Free Trial

TherapeuticsMD Q2 2024 Earnings Report

TherapeuticsMD logo
$1.12 -0.02 (-1.75%)
(As of 10:50 AM ET)

TherapeuticsMD Earnings Headlines

TherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.com
A conspiracy Trump won’t unseal
New documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.
TherapeuticsMD Shifts Focus with Lower Q3 Losses
TherapeuticsMD Reports Reduced Losses Amid Strategic Shift
See More TherapeuticsMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TherapeuticsMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TherapeuticsMD and other key companies, straight to your email.

About TherapeuticsMD

TherapeuticsMD (NASDAQ:TXMD) operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

View TherapeuticsMD Profile

More Earnings Resources from MarketBeat

Upcoming Earnings